Category: Midlines

Access Scientific Completes Study Demonstrating Superior Anti-Thrombotic Properties of POWERWAND Midlines and Extended Dwell Catheters

Access Scientific Completes Study Demonstrating Superior Anti-Thrombotic Properties of POWERWAND Midlines and Extended Dwell Catheters

May 23, 2018 – San Diego, Calif. — Access Scientific, LLC announced completion of an in vivo study demonstrating the superior anti-thrombotic (i.e., anti-clotting) property of its unique intravascular catheter material, ChronoFlex C® with BioGUARD™ technology.

The study found that ChronoFlex C with BioGUARD demonstrates thrombo-resistance where it matters most — on the surface of the blood vessel. No other catheter material has demonstrated this clinically important effect.

While other catheter manufacturers claim anti-thrombotic properties that reduce thrombus (clot) formation “on the surface of the catheter,” these anti-thrombotic claims cite in vivo or in vitro studies that show diminished thrombus formation solely on the surface of the catheter. This finding is often and mistakenly conflated with deep vein thrombosis (DVT) – a condition known to be associated with high-risk complications like bloodstream infection or blood clot embolization. There is no evidence that thrombo-resistance on the surface of the catheter has any effect on diminishing DVTs in actual patients.

Today’s announcement may serve to explain, at least in part, why Access Scientific’s POWERWAND™ catheters consistently demonstrate fewer DVTs and fewer total complications (including bloodstream infections) than other catheters used for similar purposes. “We now know it is not just the POWERWAND atraumatic insertion techniques that allow the vessel lining to remain clean and smooth,” said Steve Bierman MD, the company’s Chief Medical Officer. “It is also the catheter material, ChronoFlex C, and our patented BioGUARD processing, that makes POWERWAND anti-thrombotic both on the catheter surface and on the vessel wall.”

As hospitals continue to face the pressures of Value-Based Purchasing, novel products like POWERWAND offer solutions that both improve patient outcomes and reduce overall costs.

Access Scientific said that in the coming months it will reveal results of another completed study (pending publication). Combined with the current announcement of superior anti-thrombogenicity, this next study demonstrate the value of ChronoFlex C with BioGUARD as the ideal material for a wide variety of indwelling vascular catheters.

The Danger of Cut Catheters

The Danger of Cut Catheters

Customers often ask, Why does the POWERWAND™ have so many fewer complications than the other midlines and extended-dwell catheters we have tried?  Flip that over and it sounds like: Why do other non-POWERWAND midlines have so many more complications (DVTs, leaking, phlebitis, etc.) than POWERWAND midlines?

The answer is really quite simple: Cut catheters appear to cause irritation to the vessel lining (i.e., the intima), which in turn causes complications.  Watch this video which depicts the dangers of cut catheters quite well.

The POWERWAND is not a cut catheter; its tip is thermoformed into an atraumatic ZERO-EDGE™ transition. Beyond that, the POWERWAND guidewire has a soft, plastic domed tip.  Atraumatic POWERWAND insertion leads to superior clinical outcomes.

But there is more.  The other midlines are all made of polyurethane or a polyurethane blend.  Those polyurethane midlines with published outcome data all have higher bloodstream infection rates than POWERWAND.  Why?  Because the POWERWAND is not polyurethane. It is made of a remarkable new polymer called ChronoFlex C®, which before becoming a POWERWAND, goes through our proprietary manufacturing process.  The result: Over 20,000 catheter-days of peer-reviewed, published studies, from 5 different investigators and 6 different institutions, with ZERO bloodstream infections.

Atraumatic insertion + Thermoformed ChronoFlex C = The undisputed best-in-class, POWERWAND midline and extended-dwell catheter.  There is method to the POWERWAND magic.

POWERWAND Midline Program Guaranteed to Protect Against Costly CMS Penalties

POWERWAND Midline Program Guaranteed to Protect Against Costly CMS Penalties

Central Line-Associated Bloodstream Infections (CLABSIs), which are “Never Events,” cost hospitals significantly more than the reported $56,000 per incident.1 Because of CMS’ current reimbursement policy, CLABSIs can ultimately cost hospitals several millions of dollars.
One simple measure–the adoption of a robust midline program–can reduce central line days (CLDs) and CLABSIs, saving hospitals enormous expense. However, not all midlines can yield such important, cost-saving results. In order to affect real change and reduce central lines, facilities need to implement an evidence-based midline policy founded on published data showing low complications (especially, low infection rates) and high completion of therapy. When implementing a midline program, it is important to partner with a company that is truly interested in helping your facility reduce central lines days and CLABSIs, and that is also willing to engage in risk sharing agreements that guarantees your facility will meet targeted goals.
There is only one midline catheter proven to reduce both central line days and CLABSIs. A ground-breaking 2015 study in Infectious Disease and Clinical Practice proved the use of the POWERWAND midline decreased the total number of central line days in a ventilator ICU by 37% and reduced CLABSIs by 100% over a 12-month study period.2 These results were driven by the POWERWAND’s unparalleled performance, highlighted by its high flow rate, blood drawability, and kink resistance. With the POWERWAND, physicians recognized they had dependable access, meaning they did not need to leave high-risk central lines in place as a safeguard.  Again, this reduced CLABSIs to zero.
Not all midlines are equal, as illustrated by the data in figure 1. After using a competitive midline for ten months, across five ICUs in a large teaching hospital, the facility was still utilizing 787 CLDs per month, resulting in 15 CLABSIs over the 10-month period and a CLD utilization ratio (UR) of 0.45.  After switching to the POWERWAND, they reduced their CLDs by 30%, CLABSIs were reduced by 27% – resulting in a savings of $224,0001 — and their CLDUR dropped by 28%. Generating and sustaining these results through the use of the POWERWAND may qualify the hospital for full reimbursement and potential bonuses. The competitive midline, again, offered no such benefit. There were no bloodstream infections associated with POWERWAND midline during the data collection period. POWERWAND has over 20,000 catheters days of published scientific data without a single catheter-related bloodstream infection (CRBSI).
Figure 1 - DataFigure 1 – Data collected over two 10-month periods confirms POWERWAND offers significantly superior clinical outcomes and cost savings benefits.
Patient safety plays a major role in Value-Based Purchasing. As a result, healthcare facilities need to demonstrate they have taken all necessary steps to increase the safety of their patients. The POWERWAND Midline Program provides the hospital with a proven process that educates the staff and instills best practices throughout the facility. This process helps reduce patient risk through the elimination of unnecessary central lines. The POWERWAND provides the healthcare facility a true alternative to central lines, thereby eliminating the associated CVC risks, as well as repetitive needlesticks required by standard peripheral IV catheters (PIVs).  Patient satisfaction and safety scores rise when POWERWAND midlines are introduced.
Again, implementation of the POWERWAND’s robust midline program translates into improved reporting data:
  • The insertion of unnecessary, high-risk central lines is eliminated
  • Removal of central lines occurs sooner — when central access is no longer indicated
  • Fewer infections
    • Ultimately, this lowers SIR, which is measured by CMS
POWERWAND Central Line Day Reduction Guarantee and Cost Savings
POWERWAND has more clinical support data than any other catheter on the market. Because of the low total complications and high completion of therapy, POWERWAND allows hospitals to implement a midline program that will reduce central line days, increase staff adherence to midline policies and procedures, and increase patient satisfaction – guaranteed.
Benefits of implementing the POWERWAND Midline Program and CLD Reduction Guarantee:
  • Hard cost savings can be as great as $1003 per procedure compared to central lines
  • Up to $56,0001 in clinical savings by the reduction of just one CLABSI
  • Guaranteed reduction in central line days (risk sharing)
  • Improved standardized infection ratio (SIR)
  • Improved reimbursement through CMS Value Based Purchasing
  • Improved patient satisfaction scores
1. Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin CK, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173:2039-46.
2. Pathak R, Patel A, Enuh H et al. The Incidence of Central Line–Associated Bacteremia After the Introduction of Midline Catheters in a Ventilator Unit Population. Infect Dis Clin Prac 2015;23(3): 131-134.
3. Caparas JV, Hu JP. Safe administration of vancomycin through a novel midline catheter: a randomized, prospective clinical trial. J Vasc Access. 2014;15(4):251-256.
Full Text: POWERWAND Midline Program Guaranteed to Protect Against Costly CMS Penalties
Finally, A Solution for Hard Stick Patients.

Finally, A Solution for Hard Stick Patients.

I often travel to hospitals all over the country and hear stories from clinicians who are frustrated by peripheral IVs that don’t last. Think about your own practice – how often does it happen that you are called to start a peripheral IV on a hard stick patient only to have to restart it the next day?

Did you know that the median dwell time for an ultrasound-guided PIV is only 26 hours?  All the skill, time and effort you and your colleagues apply to the placement of these vital lines, unfortunately, results in an IV that lasts barely more than a day.  Why?  Because PIVs are simply too short (and too easily kinked) to function for any substantial time in the deeper veins of the arm and forearm.

Fortunately, there is a solution: The first true extended dwell catheter designed to extend the life of ultrasound guided peripheral IVs up to 29 days – The new POWERWAND™ EDC–3French, 6 cm (2.4 inches).

The new 3Fr, 6 cm POWERWAND is longer than a PIV, capable of power-injection up to 8 mL/sec, and is designed for the same reliable blood-drawability and extended dwell times as the POWERWAND midlines.  Made of ChronoFlex™C, this new tool in your toolbox, is ideal for renal patients–and vein preservation, in general; ultrasound guided PIVs, patient’s requiring extended treatment but who do not need the hemodilution afforded by the POWERWAND midlines.

Please consider this next great innovation from Access Scientific–the POWERWAND 3Fr, 6cm Extended Dwell Catheter.  Your patients will thank you.

Steve Bierman, MD

Chief Medical Officer

Access Scientific